Shakya Bhattacharjee1, Vijayashankar Paramanandam2,3, Atrayee Bhattacharya4. 1. Neurology, Royal Cornwall Hospital, Truro, United Kingdom and Plymouth Hospital NHS Trust, Plymouth, UK. 2. Toronto Western Hospital, Toronto, Ontario, Canada. 3. Neurology, Stanley Medical College, Chennai, Tamil Nadu, India. 4. Vidyasagar University, Midnapore, West Bengal, India.
Abstract
BACKGROUND AND PURPOSE: The dopamine transporter scan or DaT scan is abnormal in presynaptic parkinsonism but normal in nondegenerative or postsynaptic parkinsonism. In this study, we tried to ascertain the impact of DaT scan on the diagnosis and clinical management and if the semiquantitative analysis of the DaT scans has any correlation with the clinical symptoms. METHODS: The electronic and nonelectronic records of patients of Plymouth Hospital NHS Trust, United Kingdom, from 2011 to 2015 were studied to find the indication, outcome, and the impact of the scan on the management of patients. The DaT scan results were assessed visually and semiquantitatively by the Department of Nuclear Medicine. The available data were statistically analyzed with the help of Microsoft XL2010 and GraphPad software. RESULTS: A total of 258 people had DaT scan. The scan results suggested an alternate diagnosis in 50.5% of clinically diagnosed patients with Parkinson disease. Similarly, DaT scan changed the diagnosis of 40% of patients with clinical diagnosis of vascular parkinsonism, 25% of clinically diagnosed drug-induced parkinsonism, and 54% of patients with possible Lewy body dementia. Visual assessment of the DaT scan revealed that more than 60% had grade 2 abnormalities. The distribution volume ratio, a semiquantitative tool for tracer uptake, was significantly less in the patients with akinetic-rigid subtype of Parkinson disease in comparison to a tremor predominant subtype. CONCLUSIONS: Dopamine transporter scan had a significant impact in diagnosis and management.
BACKGROUND AND PURPOSE: The dopamine transporter scan or DaT scan is abnormal in presynaptic parkinsonism but normal in nondegenerative or postsynaptic parkinsonism. In this study, we tried to ascertain the impact of DaT scan on the diagnosis and clinical management and if the semiquantitative analysis of the DaT scans has any correlation with the clinical symptoms. METHODS: The electronic and nonelectronic records of patients of Plymouth Hospital NHS Trust, United Kingdom, from 2011 to 2015 were studied to find the indication, outcome, and the impact of the scan on the management of patients. The DaT scan results were assessed visually and semiquantitatively by the Department of Nuclear Medicine. The available data were statistically analyzed with the help of Microsoft XL2010 and GraphPad software. RESULTS: A total of 258 people had DaT scan. The scan results suggested an alternate diagnosis in 50.5% of clinically diagnosed patients with Parkinson disease. Similarly, DaT scan changed the diagnosis of 40% of patients with clinical diagnosis of vascular parkinsonism, 25% of clinically diagnosed drug-induced parkinsonism, and 54% of patients with possible Lewy body dementia. Visual assessment of the DaT scan revealed that more than 60% had grade 2 abnormalities. The distribution volume ratio, a semiquantitative tool for tracer uptake, was significantly less in the patients with akinetic-rigid subtype of Parkinson disease in comparison to a tremor predominant subtype. CONCLUSIONS: Dopamine transporter scan had a significant impact in diagnosis and management.
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: David S W Djang; Marcel J R Janssen; Nicolaas Bohnen; Jan Booij; Theodore A Henderson; Karl Herholz; Satoshi Minoshima; Christopher C Rowe; Osama Sabri; John Seibyl; Bart N M Van Berckel; Michele Wanner Journal: J Nucl Med Date: 2011-12-08 Impact factor: 10.057
Authors: Andreas R Kupsch; Nin Bajaj; Frederick Weiland; Antonio Tartaglione; Susanne Klutmann; Melanie Buitendyk; Paul Sherwin; Ann Tate; Igor D Grachev Journal: J Neurol Neurosurg Psychiatry Date: 2012-04-06 Impact factor: 10.154
Authors: Therese A Söderlund; John C Dickson; Elizabeth Prvulovich; Simona Ben-Haim; Paul Kemp; Jan Booij; Flavio Nobili; Gerda Thomsen; Osama Sabri; Pierre-Malik Koulibaly; Ozgur U Akdemir; Marco Pagani; Koen van Laere; Susanne Asenbaum-Nan; Jean George; Terez Sera; Klaus Tatsch; Jamshed Bomanji Journal: J Nucl Med Date: 2013-03-14 Impact factor: 10.057
Authors: C Rossi; D Frosini; D Volterrani; P De Feo; E Unti; V Nicoletti; L Kiferle; U Bonuccelli; R Ceravolo Journal: Eur J Neurol Date: 2009-12-29 Impact factor: 6.089
Authors: T Nissen; N Malek; K A Grosset; E J Newman; J Patterson; D Hadley; D G Grosset Journal: Acta Neurol Scand Date: 2013-08-20 Impact factor: 3.209
Authors: Victor L Villemagne; Frederik Barkhof; Valentina Garibotto; Susan M Landau; Agneta Nordberg; Bart N M van Berckel Journal: Radiology Date: 2021-01-19 Impact factor: 11.105